Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Clinical trial NCT02481297 · COMPLETED
Trial details
- NCT number
- NCT02481297
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-23
- Primary completion
- 2019-08-15
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.